Log in

NASDAQ:RAREUltragenyx Pharmaceutical Stock Price, Forecast & News

+0.02 (+0.03 %)
(As of 06/5/2020 04:00 PM ET)
Today's Range
Now: $69.92
50-Day Range
MA: $66.34
52-Week Range
Now: $69.92
Volume401,085 shs
Average Volume504,075 shs
Market Capitalization$4.17 billion
P/E RatioN/A
Dividend YieldN/A
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.
Read More
Ultragenyx Pharmaceutical logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.4Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.49 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:RARE



Sales & Book Value

Annual Sales$103.71 million
Book Value$11.32 per share


Net Income$-402,730,000.00
Net Margins-348.78%


Market Cap$4.17 billion
Next Earnings Date8/6/2020 (Estimated)

Receive RARE News and Ratings via Email

Sign-up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter.

Ultragenyx Pharmaceutical (NASDAQ:RARE) Frequently Asked Questions

How has Ultragenyx Pharmaceutical's stock been impacted by COVID-19 (Coronavirus)?

Ultragenyx Pharmaceutical's stock was trading at $45.35 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RARE shares have increased by 54.2% and is now trading at $69.92. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Ultragenyx Pharmaceutical?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ultragenyx Pharmaceutical in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ultragenyx Pharmaceutical.

When is Ultragenyx Pharmaceutical's next earnings date?

Ultragenyx Pharmaceutical is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Ultragenyx Pharmaceutical.

How were Ultragenyx Pharmaceutical's earnings last quarter?

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) issued its earnings results on Wednesday, May, 6th. The biopharmaceutical company reported ($1.91) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.68) by $0.23. The biopharmaceutical company had revenue of $36.31 million for the quarter, compared to analysts' expectations of $36.74 million. Ultragenyx Pharmaceutical had a negative net margin of 348.78% and a negative return on equity of 60.65%. The firm's quarterly revenue was up 99.8% on a year-over-year basis. During the same quarter last year, the business earned ($1.82) earnings per share. View Ultragenyx Pharmaceutical's earnings history.

What price target have analysts set for RARE?

13 brokerages have issued 1 year price targets for Ultragenyx Pharmaceutical's shares. Their forecasts range from $66.00 to $87.00. On average, they anticipate Ultragenyx Pharmaceutical's share price to reach $77.09 in the next year. This suggests a possible upside of 10.3% from the stock's current price. View analysts' price targets for Ultragenyx Pharmaceutical.

What are Wall Street analysts saying about Ultragenyx Pharmaceutical stock?

Here are some recent quotes from research analysts about Ultragenyx Pharmaceutical stock:
  • 1. According to Zacks Investment Research, "Ultragenyx witnessed growth in the demand for Crysvita for both children and adults with X-linked hypophosphatemia in the United States. The drug's performance has been impressive so far. The company is also expanding the label of the drug and filed an sBLA for the same for the treatment of tumor-induced osteomalacia. The company’s NDA for a potential approval of its third therapy, UX007, in fatty acid oxidation disorders is under review with the FDA. Ultragenyx continues to advance two gene-therapy clinical programs — DTX401 for glycogen storage disease type Ia and DTX301 for ornithine transcarbamylase deficiency. However, being a new commercial company with lower revenues, development or regulatory setbacks could result in higher operating expenses and the need for additional capital." (4/16/2020)
  • 2. Cowen Inc analysts commented, "Matinas reported 2Q19 with net loss of ($3.6M) and ended the period with $36.8M in cash on the balance sheet. The company should have runway through 2020 and through multiple catalysts; Omega-3 (OM3) asset MAT9001 and antifungal MAT2203 (amphotericin)." (8/15/2019)

Has Ultragenyx Pharmaceutical been receiving favorable news coverage?

Media coverage about RARE stock has trended somewhat negative recently, according to InfoTrie Sentiment. The research group scores the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Ultragenyx Pharmaceutical earned a news sentiment score of -1.5 on InfoTrie's scale. They also gave headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutUltragenyx Pharmaceutical.

Who are some of Ultragenyx Pharmaceutical's key competitors?

What other stocks do shareholders of Ultragenyx Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ultragenyx Pharmaceutical investors own include Gilead Sciences (GILD), Exelixis (EXEL), TG Therapeutics (TGTX), Portola Pharmaceuticals (PTLA), Sangamo Therapeutics (SGMO), AbbVie (ABBV), Crispr Therapeutics (CRSP), GALAPAGOS NV/S (GLPG), GW Pharmaceuticals PLC- (GWPH) and Intercept Pharmaceuticals (ICPT).

Who are Ultragenyx Pharmaceutical's key executives?

Ultragenyx Pharmaceutical's management team includes the following people:
  • Emil D. Kakkis, President, Chief Executive Officer & Director
  • Wladimir Hogenhuis, Chief Operating Officer
  • Shalini Sharp, Chief Financial Officer & Executive Vice President
  • Dennis Karl Huang, Chief Technical Operations Officer & Senior VP
  • Eric Crombez, Chief Medical Officer

What is Ultragenyx Pharmaceutical's stock symbol?

Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."

Who are Ultragenyx Pharmaceutical's major shareholders?

Ultragenyx Pharmaceutical's stock is owned by many different institutional and retail investors. Top institutional shareholders include Capital Research Global Investors (11.02%), Capital International Investors (10.28%), BlackRock Inc. (7.88%), Federated Hermes Inc. (6.73%), State Street Corp (3.74%) and Alliancebernstein L.P. (2.37%). Company insiders that own Ultragenyx Pharmaceutical stock include Emil D Kakkis, Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, Theodore Alan Huizenga and William Aliski. View institutional ownership trends for Ultragenyx Pharmaceutical.

Which institutional investors are selling Ultragenyx Pharmaceutical stock?

RARE stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, First Trust Advisors LP, BlackRock Inc., Alliancebernstein L.P., Morgan Stanley, Morgan Stanley, Cinctive Capital Management LP, and AXA. Company insiders that have sold Ultragenyx Pharmaceutical company stock in the last year include Karah Herdman Parschauer, Matthew K Fust, Shalini Sharp, and Theodore Alan Huizenga. View insider buying and selling activity for Ultragenyx Pharmaceutical.

Which institutional investors are buying Ultragenyx Pharmaceutical stock?

RARE stock was bought by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Bank of New York Mellon Corp, Capital Research Global Investors, Fred Alger Management LLC, Capital International Investors, Castleark Management LLC, Geode Capital Management LLC, and Rhenman & Partners Asset Management AB. View insider buying and selling activity for Ultragenyx Pharmaceutical.

How do I buy shares of Ultragenyx Pharmaceutical?

Shares of RARE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ultragenyx Pharmaceutical's stock price today?

One share of RARE stock can currently be purchased for approximately $69.92.

How big of a company is Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical has a market capitalization of $4.17 billion and generates $103.71 million in revenue each year. The biopharmaceutical company earns $-402,730,000.00 in net income (profit) each year or ($7.36) on an earnings per share basis.

What is Ultragenyx Pharmaceutical's official website?

The official website for Ultragenyx Pharmaceutical is www.ultragenyx.com.

How can I contact Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Court, Novato CA, 94949. The biopharmaceutical company can be reached via phone at 415-483-8800 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.